

# Integration of Artificial Intelligence (AI) into Cancer Care: Maximizing the benefits of AI and what's next?

**David R. Penberthy, MD MBA FACCC**

*Associate Professor and Program Director*

*University of Virginia Department of Radiation Oncology*

*ACCC President 2022-2023*


*October 26, 2024*

# Disclosure of Conflicts of Interest

David R. Penberthy, MD MBA  
has the following financial relationships to disclose:

- Nature of the financial relationship: UVA Health Employee
- Nature of the financial relationship: AstraZeneca Speaker
- Nature of the financial relationship: RomTech, Inc. Investor
- Nature of the financial relationship: TensorBlack, Inc. startup founder

# Learning objectives



Statement of the  
cancer problem

Current state of  
multidisciplinary  
care

AI and Future  
directions



- Powerful network of >44,000 multidisciplinary practitioners from over 2300 hospitals and practices nationwide in every state
- ~2/3 of the nation's cancer patients are treated by a member of ACCC

[www.accc-cancer.org](http://www.accc-cancer.org)



# nature medicine

AI-guided cancer radiotherapy




# Science Focus

The life and times of  
FUNGAL BODY SNATCHERS


The hunt for  
TINY KILLER ASTEROIDS

Could the  
UK'S TAP WATER RUN OUT?



SPECIAL **TIME** EDITION

## THE FUTURE OF MEDICINE



Amazing  
Breakthroughs  
How Artificial



**MONEY**  
Make the most of  
value-based care

**BUSINESS**  
Can a third-party vendor  
grow your practice?

**CAREERS**  
Dealing with  
difficult patients

**100 YEARS**  
100 years of  
the magazine  
of the medical  
profession

## 100 YEARS of Medical Economics

SMARTER BUSINESS. BETTER PATIENT CARE.

### SPECIAL REPORT DR. AI


How Doctors using ChatGPT and other AI tools  
will change health care








# Magnitude




# Worldwide Cancer Incidence



# Worldwide Cancer Incidence

Age-Standardized Rate (World) per 100 000, Incidence, Both sexes, in 2022

All cancers



All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization / International Agency for Research on Cancer concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for which there may not yet be full agreement.

Cancer TODAY | IARC  
<https://gco.iarc.who.int/today>  
Data version: Globocan 2022 (version 1.1) - 08.02.2024  
© All Rights Reserved 2024



International Agency  
for Research on Cancer





# Cancer Incidence Worldwide

Breakdown of the estimated 12.7 million new cases, World-age standardised incidence rates and the most commonly diagnosed cancers by the different regions of the world, 2008.




Source: GLOBOCAN 2008, v. 1.2, Cancer Incidence and Mortality Worldwide. IARC, 2010 (<http://globocan.iarc.fr>) Map updated February 2011

<http://info.cancerresearchuk.org/cancerstats/>

© Cancer Research UK  
Registered charity no. 1089464 (England & Wales)  
& SC041666 (Scotland)

# GDP issues




Gross domestic product

**\$27.36 trillion**

2023


National spending on  
healthcare goods and  
services

Healthcare expenditures  
as a percent of GDP



# So how are we doing?

Figure 1. Trends in Age-adjusted Cancer Death Rates by Site, Males, US, 1930-2021



Rates are age adjusted to the 2000 US standard and exclude deaths in Puerto Rico and other US territories. Note: Due to changes in ICD coding, numerator information differs from contemporary data for cancers of the liver, lung and bronchus, and colon and rectum.  
Source: US Mortality Volumes 1930 to 1959, US Mortality Data 1960 to 2021, National Center for Health Statistics, Centers for Disease Control and Prevention.  
©2024, American Cancer Society, Inc., Surveillance and Health Equity Science

## 5

### Takeaways from the Cancer Facts & Figures Report 2022



Lung cancer patients are being diagnosed earlier, and living longer.



In 2022, there will be an estimated 1,918,030 new cancer diagnoses, and 609,360 cancer deaths.



Cancer mortality is declining at an accelerating rate.





The racial, socioeconomic, and geographic disparities for preventable cancers are alarming.



The rate of advanced-stage prostate cancer diagnosis increased by 4%-6% each year from 2014 -2018.









Source: [Statistics and Graphs | Division of Cancer Control and Population Sciences \(DCCPS\)](#) accessed 2/1/24



# Cancer Prevalance and Projections in U.S. Population from 1975–2040




## REFERENCES:

Adapted from Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “Silver Tsunami”: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. *Cancer Epidemiol Biomarkers Prev.* 2016 Jul;25(7):1029-36.

Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J and Siegel RL. *Cancer Treatment and Survivorship Statistics.* CA A Cancer J Clin. 2022.





# Growth of Physicians and Administrators in U.S.



Bureau of Labor Statistics; NCHS; Himmelstein/Woolhandler analysis of CPS  
Managers shown as moving average of current year and two previous years

# US Debt and Taxes




National debt \$35T and counting  
[www.usdebtclock.org](http://www.usdebtclock.org)




# US CANCER INCIDENCE AND MORTALITY

Incidence rates, 2008-2012  
By state, all cancer types combined  
Per 100,000, age adjusted to the 2000 US standard population



Data Source: North American Association of Central Cancer Registries (NAACCR), 2015  
© 2016 American Cancer Society

Death rates, 2008-2012  
By state, all cancer types combined  
Per 100,000, age adjusted to the 2000 US standard population



Data Source: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention, 2015  
© 2016 American Cancer Society

CancerStatisticsCenter.org

What about  
the future?





# THE MEDICAL LITERATURE TSUNAMI

## Pubmed

Daily: ~4,000   Weekly: ~28,000   Monthly: ~120,000

Annually: ~1.44 million articles

## 10% oncology related

Daily - ~400   Weekly - ~2800   Monthly - ~12,000

Annually- ~144,000

These figures only represent a fraction of the medical information being generated, as they do not account for other sources like clinical trials, patents, guidelines, conference proceedings, and more. Additionally, the growth of data in fields like genomics and digital health is further accelerating the expansion of medical information.





# Growth of Guidelines

“Further approaches, including guideline stratification by evidence level and the use of artificial intelligence for decision support, should be investigated as ways to synthesize data and improve cancer decision-making.”

JAMA  
Network | **Open**

Research Letter | Oncology

## Changes in Length and Complexity of Clinical Practice Guidelines in Oncology, 1996-2019

Benjamin H. Kann, MD; Skyler B. Johnson, MD; Hugo J. W. L. Aerts, PhD; Raymond H. Mak, MD; Paul L. Nguyen, MD

Figure 1. Page Volume of National Comprehensive Cancer Network Clinical Practice Guidelines by Disease Site, 1996-2019






Figure 2. References Cited in National Comprehensive Cancer Network Clinical Practice Guidelines by Disease Site, 1996-2019






# Google HEALTH



# FEEL GOOD CASE



Test Name: Histology Analysis Multiple Marker Panel  
Specimen type: Lymph Node, Station 4R  
Performed at: NeoGenomics Laboratories

## Results

PD-L1 22C3 FDA for NSCLC: **HIGH PD-L1 EXPRESSION**  
Tumor Proportion Score: 100%  
Intensity: 3+

Reference Ranges	
High PD-L1 Expression	TPS $\geq$ 50%
PD-L1 Expression	TPS 1-49%
No PD-L1 Expression	TPS < 1%

Pan-TRK  
Not Expressed

Electronic Signature  
Scott Bourne, M.D., Pathologist

See attached report for further details.

Test Name: NeoTYPE Analysis Lung Tumor Profile  
Specimen type: Lymph Node, Station 4R  
Performed at: NeoGenomics Laboratories

## Results Summary

SNVs/Indels: **ERBB2 Y772\_A775dup**, TERT promoter c.-124C>T

Alterations Detected By FISH: FISH report is not yet completed, see subsequent report


Immuno-Oncology Biomarkers: Microsatellite Instability: MSI - Stable (MSS); **PD-L1 22C3: HIGH** PD-L1 EXPRESSION; **Tumor Mutation Burden: Intermediate**

Additional Studies: **MET Exon 14 Deletion Analysis:** Not Detected; **Pan-TRK:** Not Expressed

Pertinent Negatives: NO alterations detected in the following genes: BRAF, EGFR, KRAS


## Interpretation

- FLUORESCENCE IN SITU HYBRIDIZATION (FISH): Please refer to separate report for FISH details once results are available.
- The expression of PD-L1 suggests response to immunotherapy with anti-PD-1 or anti-PD-L1, which are FDA-approved for diverse solid tumor types.
- The VAF of the ERBB2 variant suggests ERBB2 (HER2) amplification. Clinical correlation with immunohistochemistry and/or FISH is recommended.



Her2 Exon 20 insertion mutation for which there is an FDA approved indication - Trastuzumab deruxtecan  
\*also did HER2 IHC and FISH testing, IHC reported 2+ equivocal, a distractor for someone who also treats breast cancer


# Examples from Exact Sciences and PreludeDX



Decision on individual treatment especially around the RS 25 cutoff may consider other clinical factors.

AI = Aromatase Inhibitor /  
TAM = Tamoxifen  
CI = Confidence Intervals

\*For estimated CT benefit for individual RS results, see page 2





“It is often easier  
**(and faster)** to make  
something 10x better  
than it would be to  
make it 10% better.”

— Astro Teller





# AI IN PRECISION ONCOLOGY




# WHAT IS THIS?


- Bell Labs scientists invented the transistor in 1947, and won the 1956 Nobel Prize in Physics
  - John Bardeen
  - Walter Brattain
  - William Shockley
- John McCarthy coined the term “artificial intelligence” in 1956









...AND NOW



ANNOUNCING NVIDIA BLACKWELL PLATFORM  
FOR TRILLION-PARAMETER SCALE GENERATIVE AI




The image shows a large, black, rectangular GPU module with two prominent gold-colored chips. It is positioned on the left side of the slide, with a small figure of a person standing next to it for scale.

-  **AI SUPERCHIP**  
208B Transistors
-  **2<sup>nd</sup> GEN TRANSFORMER ENGINE**  
FP4/FP6 Tensor Core
-  **5<sup>th</sup> GENERATION NVLINK**  
Scales to 576 GPUs
-  **RAS ENGINE**  
100% In-System Self-Test
-  **SECURE AI**  
Full Performance  
Encryption & TEE
-  **DECOMPRESSION ENGINE**  
800 GB/sec



# The robots are coming.


Ray Kurzweil c. 2006



# The History of AI



Parmida Belgi, PhD  
@bigdataqueen



# arXiv

<https://arxiv.org> Cornell University

Free distribution service and open access for **>2.3M** articles in physics, mathematics, computer science, quantitative biology, quantitative finance, statistics, electrical engineering and systems science, and economics

~1200 daily submissions



a place of connection, linking together people and ideas, and connecting them with the world of open science





**a**

## MACHINE AND DEEP LEARNING STUDIES ON PUBMED.COM

**TOTAL NUMBER OF STUDIES****b****STUDIES PER SPECIALTY**

Source: [https://www.reddit.com/r/applieddatahoarding/comments/14ok07m/number\\_of\\_medical\\_ai\\_studies\\_by\\_year\\_from\\_2010\\_to/](https://www.reddit.com/r/applieddatahoarding/comments/14ok07m/number_of_medical_ai_studies_by_year_from_2010_to/)

Accessed 2/1/24

# DEEP BLUE – HOW AI BEAT THE WORLD CHAMPION




May 11, 1997





# HOW AI “WATSON” BEAT TWO CHAMPIONS





February 16, 2011



# ALPHAGO BEAT LEE SEDOL



# AI VIDEO GENERATION NOW SORA | OPENAI





AI WON'T REPLACE YOU. SOMEONE USING AI WILL.



Business And Society

## AI Won't Replace Humans — But Humans With AI Will Replace Humans Without AI

August 04, 2023

The New  
World of Work  
**Karim R. Lakhani,**  
Harvard Business  
School Professor

Harvard  
Business  
Review



Original image created using beautiful ai



# IS THIS A GUTENBERG MOMENT?





# IS THIS A GUTENBERG MOMENT?

## Envisioning the Healthcare Landscape with ChatGPT

New York Medical College Explores The Opportunities And Risks Of AI On The Healthcare Industry In The Following Article Written Entirely Using ChatGPT

February 13, 2023

Opinion > Kevin, M.D.

## AI in Healthcare: Meeting HIPAA Standards With ChatGPT

— Patients deserve a commitment to privacy

by Harvey Castro, MD, MBA February 11, 2023

## ChatGPT Passes US Medical Licensing Exam Without Clinician Input

ChatGPT achieved 60 percent accuracy on the US Medical Licensing Exam, indicating its potential in advancing artificial intelligence-assisted medical education.



THE LANCET  
Digital Health

COMMENT | ONLINE FIRST

## ChatGPT: the future of discharge summaries?

Sajan B Patel • Kyle Lam

Open Access • Published: February 06, 2023 • DOI: [https://doi.org/10.1016/S2589-7500\(23\)00021-3](https://doi.org/10.1016/S2589-7500(23)00021-3)

## New and surprising evidence that ChatGPT can perform several intricate tasks relevant to handling complex medical and clinical information

Download PDF Copy



By Neha Mathur

Reviewed by Danielle Ellis, B.Sc.

Feb 13 2023

FORBES > INNOVATION > HEALTHCARE

EDITORS' PICK

## 5 Ways ChatGPT Will Change Healthcare Forever, For Better

Robert Pearl, M.D. Contributor @

Follow

## Patient-Facing

### AI Chatbots



### Wearables & Devices



### Personalized Genetics



### Mental Health



### Women's Health



### Skin



## Telehealth

### Telemedicine



### Lifestyle Management



### Disease Management



# AI in Healthcare

## Research

### Drug Discovery



### Information & Clinical Trials



### Genetic Research



## Doctor-Facing

### Medical Records



### Data Analytics



### Medical Imaging



### Hospital







OCTOBER 30, 2023

# FACT SHEET: President Biden Issues Executive Order on Safe, Secure, and Trustworthy Artificial Intelligence

[BRIEFING ROOM](#)[STATEMENTS AND RELEASES](#)

Today, President Biden is issuing a landmark Executive Order to ensure that America leads the way in seizing the promise and managing the risks of artificial intelligence (AI). The Executive Order establishes new standards for AI safety and security, protects Americans' privacy, advances equity and civil rights, stands up for consumers and workers, promotes innovation and competition, advances American leadership around the world, and more.

As part of the Biden-Harris Administration's comprehensive strategy for responsible innovation, the Executive Order builds on previous actions the President has taken, including work that led to voluntary commitments from 15 leading companies to drive safe, secure, and trustworthy development of AI.


<https://www.whitehouse.gov/briefing-room/statements-releases/2023/10/30/fact-sheet-president-biden-issues-executive-order-on-safe-secure-and-trustworthy-artificial-intelligence/>

Name this country...





## Health AI Market Size 2014 - 2021



Acquisitions of AI startups are rapidly increasing while the health market is set to register an explosive CAGR of 40% through 2021.

**Source:** Accenture (December 2017). Artificial Intelligence in Healthcare.

## GLOBAL ARTIFICIAL INTELLIGENCE IN HEALTHCARE MARKET

### ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE Market


OPPORTUNITIES AND FORECAST, 2021-2030

Artificial Intelligence (AI) in Healthcare Market is expected to reach **194.14 Billion** by 2030.

Growing at a  
**CAGR of 38.1%** (2021-2030)

Growing at a **CAGR of 48.7%**  
(2017-2023)

## GLOBAL ARTIFICIAL INTELLIGENCE IN HEALTHCARE MARKET BY GEOGRAPHY



EUROPE



ASIA-PACIFIC

**Asia-Pacific** region would exhibit the highest **CAGR of 53.4%** during 2017-2023.

Source: [Artificial Intelligence in Healthcare Market | Global Report – 2030 \(alliedmarketresearch.com\)](https://www.alliedmarketresearch.com/artificial-intelligence-in-healthcare-market)



**Shanghai 1990**



**Shanghai 2020**



Subscribe

Latest Issues

SCIENTIFIC AMERICAN

Sign In | Newsletters

COVID

Health

Mind & Brain

Environment

Technology

Space & Physics

Video

Podcasts

Opinion

Save 40% on Unlimited

Subscribe

SPACE & PHYSICS

China Reaches New Milestone in Space-Based Quantum Communications

The nation's Micius satellite successfully established an ultrasecure link between two ground stations separated by more than 1,000 kilometers

By Karen Kwon on June 25, 2020

أعرض هذا باللغة العربية

### China vs United States: GDP based on PPP

Year	United States	China
1980	~2,000	~100
1990	~5,000	~500
2000	~10,000	~2,000
2010	~15,000	~10,000
2020	~22,000	~20,000
2028	~32,000	~45,000

What is China's GDP as per PPP?

Economy of China

Statistics

GDP	\$19.373 trillion (nominal; 2023 est.) <b>\$33.014 trillion (PPP; 2023 est.)</b>
GDP rank	2nd (nominal; 2023) 1st (PPP; 2023)
GDP growth	8.4% (2021) 3.0% (2022) 5.2% (2023f) 4.5% (2024f)

Central Intelligence Agency (.gov)

https://www.cia.gov › field › country-comparison

Rank	Country		Date of Information
1	<u>China</u>	\$31,227,000,000,000	2023 est.
2	<u>United States</u>	\$24,662,000,000,000	2023 est.
3	<u>India</u>	\$13,104,000,000,000	2023 est.

April 28, 2023

# Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum

John W. Ayers, PhD, MA<sup>1,2</sup>; Adam Poliak, PhD<sup>3</sup>; Mark Dredze, PhD<sup>4</sup>; [et al](#)


**Results** Of the 195 questions and responses, evaluators preferred chatbot responses to physician responses in 78.6% (95% CI, 75.0%-81.8%) of the 585 evaluations. Mean (IQR) physician responses were significantly shorter than chatbot responses (52 [17-62] words vs 211 [168-245] words;  $t=25.4$ ;  $P<.001$ ). Chatbot responses were rated of significantly higher quality than physician responses ( $t=13.3$ ;  $P<.001$ ). The proportion of responses rated as *good* or *very good* quality ( $\geq 4$ ), for instance, was higher for chatbot than physicians (chatbot: 78.5%, 95% CI, 72.3%-84.1%; physicians: 22.1%, 95% CI, 16.4%-28.2%). This amounted to 3.6 times higher prevalence of *good* or *very good* quality responses for the chatbot. Chatbot responses were also rated significantly more empathetic than physician responses ( $t=18.9$ ;  $P<.001$ ). The proportion of responses rated *empathetic* or *very empathetic* ( $\geq 4$ ) was higher for chatbot than for physicians (physicians: 4.6%, 95% CI, 2.1%-7.7%; chatbot: 45.1%, 95% CI, 38.5%-51.8%; physicians: 4.6%, 95% CI, 2.1%-7.7%). This amounted to 9.8 times higher prevalence of *empathetic* or *very empathetic* responses for the chatbot.

**Conclusions** In this cross-sectional study, a chatbot generated quality and empathetic responses to patient questions posed in an online forum. Further exploration of this technology is warranted in clinical settings, such as using chatbot to draft responses that physicians could then edit. Randomized trials could assess further if using AI assistants might improve responses, lower clinician burnout, and improve patient outcomes.



# AI IN RADIATION ONCOLOGY

## Automatic delineation of tumors and organs at risk



Comparison of sketch speed of target area:

AI takes 10-20 minutes

Manual work takes 4-5 hours

# CAPACITY MANAGEMENT

## LeanTaaS Overview

**Silicon Valley, Charlotte and Boston based software company**

- PhDs in Mathematics, Software Engineers, Product Managers, Operations Experts, Hospital Executives

**\$350+ Million invested in predictive analytics platform “iQueue”**

**Mission: Unlock capacity of scarce assets using predictive and prescriptive analytics:**

- Improve patient access
- Increase volumes and revenues
- Reduce wait time for patients
- Reduce operating costs
- Defer the need for facility expansion

**6 Patents Pending**

**Awards & 3rd Party Validation**



**Gartner**



# 605

Leading Hospitals

# 14 of top 20

Health Systems

# 175

Health Systems

# 46


States in the U.S.





# BRIDGING SCIENCE & PRECISION PATIENT CARE


Phenome (WGS + LPR) cohorts can *stratify* diseases, from first principles.



Source:  Schork, Nicholas. [Personalized Medicine: Time for one-person trials.](#) Nature. Vol 520, April 2015.



# BRIDGING SCIENCE & PRECISION PATIENT CARE





# CHANGING THE HEALTHCARE LANDSCAPE

Streamlining Workflows

Reducing Costs

Improving Collaboration

Advancing Research

Empowering Patients



Technology  
changes.....



## 03

```

      1000
    0111001
  0011110100100
00011010110101110001
001011110110111101011100
0011011111000111010001
110001011110100010111011
110110001011101000101111
101001000001010010110111
1010111000101101110001011
101111101011101111011000
1011011101111101110001011
111000101111010111101100
1111011011010111101001
1011110111101101011100
1011110011011011
101111011110001

```

O=C1C(=O)C(=O)C(=O)C1

A hand holding a pair of tweezers is shown picking up a small, glowing blue DNA double helix structure. The background is dark, and there are other glowing blue DNA structures visible, suggesting a laboratory or research setting.

# How CRISPR works

1. The Cas9 protein forms a complex with guide RNA in a cell
2. This complex attaches to a matching genomic DNA sequence adjacent to a spacer (yellow segment)

The diagram illustrates the CRISPR-Cas9 system. A large DNA double helix is shown on the left. On the right, a Cas9 protein (represented by a blue and orange structure) is shown forming a complex with a guide RNA (represented by a red line). This complex then attaches to a matching genomic DNA sequence (represented by a blue and orange double helix) adjacent to a spacer (yellow segment).

**OVERVIEW**  
At Illumina, their goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies






*In 2012, scientists at the University of Leicester decided to print out a complete version of the human genome. When they were done, they had a 130-volume monument to humanity's essence—a seemingly endless sequence of As, Ts, Cs, and Gs in four-point type. Curiously, the printing project's costs already exceeded the costs of actually sequencing the genome anew. Since then, the price differential has only grown. Cas Kramer (Univ. Leicester) »*



# THE CRISPR REVOLUTION



*“The term ‘Holy Grail’ is overused in science,” Davies writes, “but if fixing a single letter in the genetic code of a fellow human being isn’t the coveted chalice of salvation, I don’t know what is.”*

# INNOVATION THAT BENEFITS PROVIDERS AND PATIENTS

MEDTECH

## FDA clears Paige's AI as first program to spot prostate cancer in tissue slides

By Conor Hale • Sep 22, 2021 11:59am

JAMA | Original Investigation | INNOVATIONS IN HEALTH CARE DELIVERY

## Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs

EDITORIAL

## Deep Learning Algorithms for Detection of Lymph Node Metastases From Breast Cancer Helping Artificial Intelligence Be Seen

Jeffrey Alan Golden, MD

## AI Partnership to Advance Brain Tumor Research, Treatment

Hackensack Meridian Health and Neosoma, Inc. have announced a collaboration aimed at tackling difficult-to-treat brain tumors through the use of artificial intelligence.

Radiology: Artificial Intelligence

## Improving Breast Cancer Detection Accuracy of Mammography with the Concurrent Use of an Artificial Intelligence Tool

Serena Pucile, PhD • January Lopez, MD • Pauline Chone, MPhil • Thomas Bertinotti, MSc • Joao Marie Grouin, PhD • Pierre Fillard, PhD

NEJM  
Evidence

Published March 28, 2022

NEJM Evid 2022; 1 (5)

DOI: 10.1056/EVIDoa2100058

ORIGINAL ARTICLE

## AI Estimation of Gestational Age from Blind Ultrasound Sweeps in Low-Resource Settings

Teeranan Pokrakarn, Ph.D.,<sup>1</sup> Juan C. Prieto, Ph.D.,<sup>2</sup> Joan T. Price, M.D., M.P.H.,<sup>3,4</sup> Margaret P. Kasaro, M.D., M.P.H.,<sup>3,5</sup> Ntazana Sindano, B.Sc.,<sup>3</sup> Hina R. Shah, M.S.,<sup>2</sup> Marc Peterson, M.S.,<sup>4</sup> Mutinta M. Akapelwa, B.Sc.,<sup>3</sup> Filson M. Kapilya, B.Sc.,<sup>3</sup> Yuri V. Sebastião, Ph.D.,<sup>4</sup> William Goodnight III, M.D., M.S.,<sup>4</sup> Elizabeth M. Stringer, M.D., M.Sc.,<sup>4</sup> Bethany L. Freeman, M.P.H., M.S.W.,<sup>4</sup> Lina M. Montoya, Ph.D.,<sup>1</sup> Benjamin H. Chi, M.D., M.Sc.,<sup>3,4</sup> Dwight J. Rouse, M.D., M.S.P.H.,<sup>6</sup> Stephen R. Cole, Ph.D.,<sup>7</sup> Bellington Vwalika, M.D., M.Sc.,<sup>4,5</sup> Michael R. Kosorok, Ph.D.,<sup>1</sup> and Jeffrey S. A. Stringer, M.D.<sup>3,4</sup>

JAMA Guide to Statistics and Methods

## Using Free-Response Receiver Operating Characteristic Curves to Assess the Accuracy of Machine Diagnosis of Cancer

Cheryl S. Moskowitz, PhD

JAMA | Original Investigation

## Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer


Babak Ehteshami Bejnordi, MS; Mitko Veta, PhD; Paul Johannes van Diest, MD, PhD; Bram van Ginneken, PhD; Nico Karssemeijer, PhD; Geert Litjens, PhD; Jeroen A. W. M. van der Laak, PhD; and the CAMELYON15 Consortium

HEALTH TECH

## White House unveils CancerX innovation accelerator, new funding for cancer screenings on Moonshot anniversary




# WHAT IS AUGMENTED INTELLIGENCE?



## ARTIFICIAL INTELLIGENCE (AI)


Incorporating human intelligence  
into machines



## AUGMENTED AI

Use of artificial intelligence  
to improve human performance

# GOALS OF AUGMENTED AI



**Accuracy**



**Precision  
Standardization**



**Efficiency**



**Major Errors  
Omissions**




**Clarity of  
Communication**




# STANDARD OF CARE VS AUGMENTED INTELLIGENCE

## Standard of Care




## Augmented Intelligence



# AI IN PRECISION ONCOLOGY JOURNAL

- Be a Guest Editor
- Submit a Feature Paper
- Submit Research and Review Papers
- Seeking National & International Board Members



**AI** IN PRECISION ONCOLOGY  
Mary Ann Liebert, Inc. publishers

FOR IMMEDIATE RELEASE  
FROM MARY ANN LIEBERT, INC., PUBLISHERS

Contact: Kathryn Ryan  
Mary Ann Liebert, Inc., publishers  
914-740-2100  
kryan@liebertpub.com

### Evaluating AI-Based Nodal Contouring in Head and Neck Cancer


New Rochelle, NY, February 8, 2024—A new study evaluates an artificial intelligence (AI)-based algorithm for autocontouring prior to radiotherapy in head and neck cancer. Manual contouring to pinpoint the area of treatment requires significant time, and an AI algorithm to enable autocontouring has been introduced. The study is published in the peer-reviewed journal *AI in Precision Oncology*. [Click here to read the article now](#).

Sushil Beriwal, from Allegheny Health Network, and Varian, and coauthors, analyzed 108 patients with head and neck cancers. The automated nodal contours were evaluated using a 4-point scale: a score of 4 was clinically usable with no edits; a score of 3 required minor edits; a score of 2 required major edits; and a score of 1 required complete re-contouring of the region."

The mean score for autocontouring was 3.56 +/- .40.

"Overall, the AI segmented autocontouring performed well with significant time saving and were clinically usable with no or minor edits the majority of times," concluded the investigators."

"The recent findings underscore the efficiency and reliability of AI in enhancing radiotherapy planning for head and neck cancer. With autocontouring algorithms demonstrating clinically usable results in the majority of cases, we're at the brink of a major shift in treatment preparation. This advancement not only promises significant time savings for healthcare professionals but also opens the door to potentially more precise and patient-specific treatments. As we move forward, the integration of AI into oncological care represents a pivotal step towards more streamlined and effective patient care," says **Douglas Flora, MD**, Editor-in-Chief of *AI in Precision Oncology*.



**AI** IN PRECISION ONCOLOGY  
Mary Ann Liebert, Inc. publishers

You've read the inaugural issue...

[Now make sure you have access to all the incredible content coming in 2024](#)


From cutting-edge research and reviews to dynamic commentary and perspectives, *AI in Precision Oncology* provides the tools to enable AI's responsible and effective use in oncology for the benefit of healthcare providers and patients.

[You can't afford to miss a minute of the incredible content coming soon. Make sure you have access by asking your library to subscribe today.](#)

[REQUEST ACCESS](#)

*AI in Precision Oncology* is more than a scientific or medical journal; it is a mission-driven initiative to harness the power of AI in improving oncology care. We aim to shape an AI-enabled health care system that is equitable, efficient, and patient centered – making health care more human."

Douglas Flora, Editor-in-Chief




[Ask Your Library to Subscribe](#)

© 2024 Mary Ann Liebert, Inc., publishers. All Rights Reserved

140 Huguenot Street, 3rd Floor, New Rochelle, NY, 10801-5215, USA

Refine your email preferences:  
[Liebert Connect](#)



**AI** IN PRECISION ONCOLOGY  
Mary Ann Liebert, Inc. publishers

FOR IMMEDIATE RELEASE  
MARY ANN LIEBERT, INC., PUBLISHERS

Contact: Kathryn Ryan  
Mary Ann Liebert, Inc., publishers  
914-740-2100  
kryan@liebertpub.com

### Evaluating AI-Based Nodal Contouring in Head and Neck Cancer


New Rochelle, NY, February 8, 2024—A new study evaluates an artificial intelligence (AI)-based algorithm for autocontouring prior to radiotherapy in head and neck cancer. Manual contouring to pinpoint the area of treatment requires significant time, and an AI algorithm to enable autocontouring has been introduced. The study is published in the peer-reviewed journal *AI in Precision Oncology*. [Click here to read the article now](#).

Sushil Beriwal, from Allegheny Health Network, and Varian, and coauthors, analyzed 108 patients with head and neck cancers. The automated nodal contours were evaluated using a 4-point scale: a score of 4 was clinically usable with no edits; a score of 3 required minor edits; a score of 2 required major edits; and a score of 1 required complete re-contouring of the region."

The mean score for autocontouring was 3.56 +/- .40.

"Overall, the AI segmented autocontouring performed well with significant time saving and were clinically usable with no or minor edits the majority of times," concluded the investigators."

"The recent findings underscore the efficiency and reliability of AI in enhancing radiotherapy planning for head and neck cancer. With autocontouring algorithms demonstrating clinically usable results in the majority of cases, we're at the brink of a major shift in treatment preparation. This advancement not only promises significant time savings for healthcare professionals but also opens the door to potentially more precise and patient-specific treatments. As we move forward, the integration of AI into oncological care represents a pivotal step towards more streamlined and effective patient care," says **Douglas Flora, MD**, Editor-in-Chief of *AI in Precision Oncology*.




**AI** IN PRECISION ONCOLOGY  
Mary Ann Liebert, Inc. publishers

Issue Now Available

Douglas Flora, MD

"Oncology is more than a scientific or medical endeavor; it is a mission-driven initiative to harness the power of artificial intelligence in precision oncology care. We aim to shape an AI-enabled health care system that is equitable, efficient, and patient centered – making health care more human." – Dr. Douglas Flora



Announce the publication of the inaugural issue of *AI in Precision Oncology*. The issue is available with free access available until February 28th:

*AI in Precision Oncology* [Read Now](#)

Artificial Intelligence in Precision Oncology: An Interview with Eric Topol  
Douglas B. Flora, MD [Read Now](#)

Douglas B. Flora, MD  
Damian Doherty [Read Now](#)

"Phenomics and Hyperscale AI for Health Care  
Penberthy [Read Now](#)

Artificial Intelligence? An Insight for Oncologists  
Douglas B. Flora, MD [Read Now](#)

Generative Artificial Intelligence in Clinical Oncology Contexts  
Nikhil G. Thaker [Read Now](#)

Papers: The Future of Cancer Screening—Leveraging AI and Precision Oncology  
Douglas B. Flora, MD [Read Now](#)

Papers: Ethics and Regulation of AI in Precision Oncology  
Douglas B. Flora, MD [Read Now](#)



“If you’re teaching today what you were five years ago;  
either the field is dead or you are.”



-- Noam Chomsky

## 21<sup>st</sup> century curricular emphasis

- **Knowledge capture and curation:** Teaching students to distinguish between information and knowledge. Stresses knowledge capture and curation not information retention.
- **Deep understanding of probabilistic reasoning:** understanding probabilities and communicating and applying them meaningfully
- **Collaboration with and management of AI applications**
- **Cultivation of empathy and compassion**



# CURRENT LIMITATIONS AND CHALLENGES

## Healthcare Algorithms Are Biased, and the Results Can Be Deadly

Deep-learning algorithms suffer from a fundamental problem: They can adopt unwanted biases from the data on which they're trained. In healthcare, this can lead to bad diagnoses and care recommendations.

### How Bias Can Creep into Health Care Algorithms and Data

Health care is rife with bias. Without careful attention, AI will perpetuate those inequities.


### Biases in Artificial Intelligence Led to Healthcare Disparities

Researchers from the US and China note that several biases found in artificial intelligence design perpetuate healthcare disparities.

Racial bias in a medical algorithm favors white patients over sicker black patients

**A US government study confirms most face recognition systems are racist**

Amazon Still Pushing Biased Facial-Recognition Software To Law Enforcement, MIT Researcher Contends





# Easter Parades in New York City

Year 1900: One Motor Vehicle



Year 1913: One Horse & Carriage





**Change is accelerating**  
**Stay alert & engaged**  
**Be open to possibilities**  
**...and buckle up!**





The future is bright!





A close-up photograph of two young women smiling warmly at the camera. The woman on the left has long, wavy brown hair and blue eyes, wearing a gold chain-link earring. The woman on the right has short, dark, wavy hair and is wearing large, ornate gold earrings with pink and red teardrop-shaped stones. Both women are wearing light-colored, possibly white, strapless tops. The background is a soft-focus green, suggesting an outdoor setting with foliage. The text "Thank you!" is overlaid in the top right corner in a white, sans-serif font.

Thank you!




---

## THANK YOU!



dp4j@uvahealth.org



<https://home.liebertpub.com/publications/ai-in-precision-oncology/679>



David R. Penberthy, MD MBA



David Penberthy



@drpenberthy



@drpjkp



# Q & A



# References

1. Jakubowski DM, Bailey H, Abran A, et al. Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test. *J Surg Oncol*. 2020;122(4):611-618. doi: 10.1002/jso.26050
2. Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. *J Mol Diagn*. 2017;19(1):4-23. doi: 10.1016/j.jmoldx.2016.10.002
3. Li K, Lou H, Huang L, et al. Microsatellite instability: a review of what the oncologist should know. *Cancer Cell Int*. 2020;20:16. doi: 10.1186/s12935-019-1091-8
4. Brauns J, Pauwels P. Tumor mutational burden: a review. *Belg J Med Oncol*. 2020;14(1):4-7. <https://www.bjmo.be/journal-article/tumour-mutational-burden-a-review/>
5. Albain KS, Zlobin AY, Covington KR, et al. Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model. 2014 San Antonio Breast Cancer Symposium. 2014; San Antonio, Texas.
6. Colomer R, Mondejar R, Romero-Laorden N, et al. When should we order a next generation sequencing test in a patient with cancer? *EClinicalMedicine*. 2020;25:100487. doi: 10.1016/j.eclinm.2020.100487
7. IQVIA. Supporting precision oncology: targeted therapies, immuno-oncology, and predictive biomarker-based medicines. Published August 11, 2020. <https://www.iqvia.com/insights/the-iqvia-institute/reports/supporting-precision-oncology>
8. Torres GF, Bonilla CE, Buitrago G, et al. How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review. *Crit Rev Oncol Hematol*. 2021;166:103459. doi: 10.1016/j.critrevonc.2021.103459
9. Chakravarty D, Johnson A, Sklar J, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. *J Clin Oncol*. 2022;40(11):1231-1258. doi: 10.1200/JCO.21.02767
10. Sarhadi VK, Armengol G. Molecular biomarkers in cancer. *Biomolecules*. 2022;12(8):1021. <https://doi.org/10.3390/biom12081021>
11. Pritchard D, Goodman C, Nadauld LD. Clinical utility of genomic testing in cancer care. *JCO Precis Oncol*. 2022;6:e2100349. doi: 10.1200/PO.21.00349
12. Ray T. Industry interest in pan-cancer indications growing with FDA support despite challenges. Published May 29, 2019. Accessed February 13, 2023. <https://www.precisiononcologynews.com/cancer/industry-interest-pan-cancer-indications-growing-fda-support-despite-challenges#.Y-p523bMJD8>
13. Pagliarulo N. Roche cancer drug the 3rd approved for pan-tumor use. Published August 15, 2019. Accessed February 13, 2023. <https://www.biopharmadive.com/news/roche-rozlytrek-cancer-drug-approval-tumor-agnostic/561027/#:~:text=Rozlytrek%2C%20as%20the%20drug%20will,another%20mutation%20known%20as%20ROS1.>
14. U.S. Food & Drug Administration. FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor. Published August 15, 2019. Accessed February 13, 2023. <https://www.fda.gov/news-events/press-announcements/fda-approves-third-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor>
15. Liu R, Rizzo S, Whipple S, Pal N, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. *Nature*. 2021;592:629-633. <https://www.nature.com/articles/s41586-021-03430-5>
16. Benedum C, Adamson B, Cohen AB, et al. P57 machine learning-accelerated outcomes research: A real-world case study of biomarker-associated overall survival in oncology. *Value Health*. 2022;25(12):S13-S14. <https://doi.org/10.1016/j.jval.2022.09.069>



# REFERENCES

1. American Cancer Society. Cancer facts & figures: 2019. Published 2019. Accessed August 15, 2022. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf>
2. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin*. 2019;69(5):363-385. doi: 10.3322/caac.21565
3. Weir HK, Thompson TD, Stewart SL, et al. Cancer incidence projections in the United States between 2015 and 2050. *Prev Chronic Dis*. 2021;18:210006. doi: <http://dx.doi.org/10.5888/pcd18.210006>
4. American Cancer Society. Cancer facts & figures: 2022. Accessed August 15, 2022. <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html>
5. Yang W, Williams JH, Hogan PF, et al. Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage. *J Oncol Pract*. 2014;10(1):39-45. doi: 10.1200/JOP.2013.001319
6. Google. Tacoma, Washington. Accessed August 16, 2022. <https://www.google.com/maps/place/Tacoma,+WA/@47.3945599,-123.1267825,8.29z/data=!4m5!3m4!1s0x549054ee2b659567:0x62219c07ebb09e82!8m2!3d47.2528768!4d-122.4442906>
7. Hale C. FDA clears Paige's AI as first program to spot prostate cancer in tissue slides. Published September 22, 2021. Accessed August 17, 2022. <https://www.fiercebiotech.com/medtech/fda-clears-paige-s-ai-as-first-program-to-spot-prostate-cancer-amid-tissue-slides#:~:text=MedTech-,FDA%20clears%20Paige's%20AI%20as%20first%20program,prostate%20cancer%20in%20tissue%20slides&text=Tech%20companies%20have%20been%20questing,clearance%20to%20do%20just%20that>
8. Moskowitz CS. Using free-response receiver operating characteristic curves to assess the accuracy of machine diagnosis of cancer. *JAMA*. 2017;318(22):2250-2251. doi: 10.1001/jama.2017.18686
9. Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. *JAMA*. 2016;316(22):2402-2410. doi:10.1001/jama.2016.17216
10. Pokaprakarn T, Prieto JC, Price JT, et al. AI estimation of gestational age from blind ultrasound in low-resource settings. *NEJM Evid*. 2022. doi: <https://doi.org/10.1056/EVIDoa2100058>
11. Golden JA. Deep learning algorithms for detection of lymph node metastases from breast cancer: helping artificial intelligence be seen. *JAMA*. 2017;318(22):2184-2186. doi: 10.1001/jama.2017.14580
12. Pacile S, Lopez J, Chone P, et al. Improving breast cancer detection accuracy of mammography with the concurrent use of an artificial intelligent tool. *Radiol Artif Intell*. 2020;2(6):e190208. doi: 10.1148/ryai.2020190208
13. Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. *JAMA*. 2017;318(22):2199-2210. doi:10.1001/jama.2017.14585
14. Ibex Medical Analytics. Prostate biopsy with cancer probability (blue is low, red is high). Published July 27, 2020. Accessed August 17, 2022. <https://www.eurekalert.org/news-releases/558575>
15. Indigo BioAutomation. Process, review, and release GC/LC-MS data. Accessed August 17, 2022. <https://info.indigobio.com/ascent-demo>
16. LeanTaaS, Becker's Hospital Review. How Novant Health optimized OR capacity to restore elective surgery & achieve stronger financial health. Accessed August 17, 2022. [https://iqueue.leantaas.com/Beckers-Feb-23-2021-Community-Hospitals-Virtual-Forum\\_Registration.html](https://iqueue.leantaas.com/Beckers-Feb-23-2021-Community-Hospitals-Virtual-Forum_Registration.html)
17. LeanTaaS. Unlocking healthcare capacity and access with technology and lean transformation. Accessed August 17, 2022. <https://iqueue.leantaas.com/OR-manager-unlocking-healthcare-capacity-eBook-download.html>
18. Epic. Homepage. Accessed August 17, 2022. <https://www.epic.com/>
19. Copan. PhenoMatrix®. Accessed August 17, 2022. <https://www.copanusa.com/full-lab-automation-and-artificial-intelligence/phenomatrix/>
20. Eon. Eon Blogs: Eon + Epic. Published February 11, 2021. Accessed August 17, 2022. <https://eonhealth.com/blog/eon-epic/#:~:text=Eon%20is%20a%20powerful%20supplement%20to%20Epic.&text=The%20Eon%20solution%20incorporates%20high,and%20achieve%20documented%20patient%20outcomes>
21. Access Intelligence, LLC. ORManager. Accessed August 17, 2022. <https://www.ormanager.com/>
22. Michele Doying, The Verge. A doctor explains how artificial intelligence could improve the patient-doctor bond. Published March 12, 2019. Accessed August 12, 2022. <https://www.theverge.com/2019/3/12/18261718/eric-topol-deep-medicine-artificial-intelligence-algorithms-health-science-interview>